Viridian Therapeutics, Inc. Common Stock
Symbol: VRDN (NASDAQ)
18.87
▼ (-3.97%) -0.780
Company Description:
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Key Stats
- Today's Open: $19.56
- Today's High: $20.314
- Today's Low: $18.865
- Today's Volume: 448.17K
- Yesterday Close: $19.65
- Yesterday High: $20.34
- Yesterday Low: $19.475
- Yesterday Volume: 467.27K
- Last Min Volume: 25
- Last Min High: $18.87
- Last Min Low: $18.87
- Last Min VWAP: $18.87
Company Profile
- Name: Viridian Therapeutics, Inc. Common Stock
- Website: https://www.viridiantherapeutics.com
- Listed Date: 2014-06-18
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001590750
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.54B
- Round Lot: 100
- Outstanding Shares: 81.66M
- Asset Type: CS
RECENT FILINGS FOR VRDN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | S-3ASR | View |
| 2025-08-06 | S-8 | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-30 | 8-K | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-06-24 | 8-K | View |
| 2025-06-11 | 4 | View |
| 2025-05-20 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-06 | 10-Q | View |
| 2025-05-06 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-25 | DEF 14A | View |
Latest News on VRDN